已知G蛋白偶联受体(GPCR)及其下游信号通路参与了肿瘤的发展,但特异性GPCR拮抗剂的治疗潜能是有限的,因为肿瘤的生长是被几个GPCR同时激发的。最近的研究发现,选择性抑制异源三聚体G蛋白亚基复合体的新抗癌药是阻断GPCR信号通路的新选择。科研人员通过检索化学数据库发现了一个 G-protein coupled receptors (GPCRs) and their downstream signaling pathways are known to be involved in the development of tumors, but the therapeutic potential of specific GPCR antagonists is limited because tumor growth is stimulated simultaneously by several GPCRs. Recent studies have found that new anticancer drugs that selectively inhibit the heterotrimeric G protein subunit complex are new choices for blocking the GPCR signaling pathway. Researchers found one by searching the chemical database